A5034477385- Psoriasis: Treatment and Pathogenesis
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Asthma and respiratory diseases
- Immunotherapy and Immune Responses
- Urticaria and Related Conditions
- Autophagy in Disease and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Mast cells and histamine
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Synthesis of Tetrazole Derivatives
- Immune Cell Function and Interaction
- Autoimmune Bullous Skin Diseases
- Cytokine Signaling Pathways and Interactions
King's College London
2016-2023
Cambridge University Hospitals NHS Foundation Trust
2023
Addenbrooke's Hospital
2023
University of Cambridge
2023
The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions neutrophil-filled pustules. disease, which often manifests with concurrent vulgaris, can have an acute systemic (generalized [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua Hallopeau [ACH]) presentation. Although mutations been uncovered in IL36RN AP1S3, the rarity disease has hindered study genotype-phenotype correlations.We sought to characterize clinical...
Prominent skin involvement is a defining characteristic of autoinflammatory disorders caused by abnormal IL-1 signaling. However, the pathways and cell types that drive cutaneous features remain poorly understood. We sought to address this issue investigating pathogenesis pustular psoriasis, model with predominant manifestations. specifically characterized impact mutations affecting AP1S3, disease gene previously identified our group validated here in newly ascertained patient resource....
Generalized pustular psoriasis (GPP) is a potentially life-threatening skin disease, associated with IL36RN mutations. encodes the interleukin (IL)-36 receptor antagonist (IL-36Ra), protein that downregulates activity of IL-36 cytokines by blocking their (IL-36R). While GPP can be treated IL-36R inhibitors, structural underpinnings IL-36Ra/IL-36R interaction remain poorly understood. Here, we sought to address this question systematically investigating effects mutations.We experimentally...
Background: Pembrolizumab is approved for the treatment of advanced and resected melanoma was originally licensed as a 3-weekly infusion (Q3W). In April 2019, 6-weekly schedule (Q6W) also approved. We retrospectively reviewed pembrolizumab prescribing patients with across multiple UK centres to compare safety efficacy Q6W Q3W in real-world clinical practice.Methods: Case notes treated between 2019 August 2020 at 8 were reviewed. Pre-specified baseline characteristics cohorts compared, well...